Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Sirolimus in RUNX1 Familial Platelet Disorder
NCT07844694Phase 1Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sirolimus in Familial Platelet Disorder With Associated Myeloid Malignancy (FPDMM), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Incidence of grade 3+ treatment-related adverse events. Started Oct 2026; status: recruiting.
02
Drugs
sirolimus
03
Conditions
Familial Platelet Disorder With Associated Myeloid Malignancy (FPDMM)
Beyond the preview
Go deeper on NCT07844694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844694.